<DOC>
	<DOC>NCT00257621</DOC>
	<brief_summary>This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone. This study has a 48 week duration and is open to both treatment naive and experienced patients who are HIV positive. There are 3 intensive pharmacokinetic (PK) visits.</brief_summary>
	<brief_title>GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion criteria: HIV1 infected subjects. Females must be of either nonchildbearing potential or have a negative pregnancy test at Screening and agree to use a protocol approved method of contraception. Plasma HIV1 RNA (viral load) &gt;/=1,000 copies/mL at Screening. CD4+ cell count &gt;/= 200 cells/mm3 at Screening. Be able to receive at least two of the following NRTIs (3TC, FTC, d4T, ddI or ZDV)to build a nucleoside backbone regimen. Willing and able to provide signed and dated written informed consent prior to study entry. Exclusion criteria: Active CDC Class C disease. Pregnant or breastfeeding women. Protocolspecified laboratory abnormalities at Screening. Personal or family history of autoimmune disease. History or current indication of thyroid dysfunction or current thyroid gland abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HIV-1 protease inhibitor GW640385 ritonavir RTV</keyword>
</DOC>